The biopharmaceutical industry is evolving toward highly-personalized patient-centric therapies. While these next-generation treatments have brought newfound hope to patients, they have further complexified one of the most intricate and high-stakes supply chains. Each product can have hundreds of variants depending on the process complexity, country, quality standards, and regulatory approvals across the end-to-end product flow.
Additionally, a fragmented IT landscape, a reliance on manual spreadsheet-based planning processes, and a lack of visibility and collaboration with external partners greatly hinder biopharma companies’ supply chain planning and decision-making abilities.
Learn about the factors driving biopharmaceutical supply chain complexity and how the industry can address them to create a strategic advantage.